On September 17, 2024, Aditxt, Inc., a biotech company, issued a senior note valued at $923,077 to an accredited investor for a purchase price of $600,000. This note, which does not bear interest, is set to mature on the earlier of June 18, 2025, or upon the company's raising of at least $1 million in securities offerings. Aditxt has the option to prepay the note without penalty and is obligated to allocate 30% of the gross proceeds from certain stock sales to repay the note. Concurrently, on September 18, 2024, Aditxt purchased 260 shares of Evofem Biosciences, Inc.'s Series F-1 Convertible Preferred Stock for $260,000 and entered into a Registration Rights Agreement, requiring Evofem to file a registration statement for the resale of shares converted from the preferred stock. Additionally, Aditxt's subsidiary, Pearsanta, Inc., signed a Market Development Collaboration Agreement with Evofem to develop a go-to-market plan for Pearsanta's Mitomic Endometriosis Test (MET) and granted Evofem a right of first refusal on the U.S. distribution of MET for 24 months.

On September 17, 2024, Aditxt, Inc., a biotech company, issued a senior note valued at $923,077 to an accredited investor for a purchase price of $600,000. This note, which does not bear interest, is set to mature on the earlier of June 18, 2025, or upon the company's raising of at least $1 million in securities offerings. Aditxt has the option to prepay the note without penalty and is obligated to allocate 30% of the gross proceeds from certain stock sales to repay the note. Concurrently, on September 18, 2024, Aditxt purchased 260 shares of Evofem Biosciences, Inc.'s Series F-1 Convertible Preferred Stock for $260,000 and entered into a Registration Rights Agreement, requiring Evofem to file a registration statement for the resale of shares converted from the preferred stock. Additionally, Aditxt's subsidiary, Pearsanta, Inc., signed a Market Development Collaboration Agreement with Evofem to develop a go-to-market plan for Pearsanta's Mitomic Endometriosis Test (MET) and granted Evofem a right of first refusal on the U.S. distribution of MET for 24 months.